Inogen, Inc $INGN Shares Sold by Divisadero Street Capital Management LP

Divisadero Street Capital Management LP trimmed its position in shares of Inogen, Inc (NASDAQ:INGN) by 80.6% during the third quarter, Holdings Channel reports. The firm owned 88,136 shares of the medical technology company’s stock after selling 367,253 shares during the quarter. Divisadero Street Capital Management LP’s holdings in Inogen were worth $720,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. AQR Capital Management LLC raised its stake in shares of Inogen by 30.1% during the 1st quarter. AQR Capital Management LLC now owns 564,032 shares of the medical technology company’s stock worth $4,022,000 after buying an additional 130,381 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new stake in Inogen in the 1st quarter valued at about $85,000. Goldman Sachs Group Inc. increased its holdings in Inogen by 16.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 284,180 shares of the medical technology company’s stock valued at $2,026,000 after acquiring an additional 41,002 shares in the last quarter. Jane Street Group LLC purchased a new position in Inogen during the 1st quarter valued at about $463,000. Finally, Geode Capital Management LLC raised its position in Inogen by 7.9% during the second quarter. Geode Capital Management LLC now owns 615,279 shares of the medical technology company’s stock worth $4,326,000 after acquiring an additional 44,860 shares during the last quarter. Institutional investors and hedge funds own 89.94% of the company’s stock.

Inogen Price Performance

Inogen stock opened at $6.06 on Monday. Inogen, Inc has a 12-month low of $5.34 and a 12-month high of $9.13. The stock has a market capitalization of $165.01 million, a P/E ratio of -7.05 and a beta of 1.76. The firm’s 50-day moving average is $6.14 and its two-hundred day moving average is $7.14.

Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Tuesday, February 24th. The medical technology company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.10. The business had revenue of $81.72 million during the quarter, compared to analyst estimates of $82.00 million. Inogen had a negative net margin of 6.52% and a negative return on equity of 11.56%. As a group, analysts forecast that Inogen, Inc will post -1.73 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inogen in a report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $11.00.

Inogen Company Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.